Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Roblin

Showing results (181-190 of 252) with videos related to

Pageof 26
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 10, 2019
Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's DiseaseNinon Soufflet, Gilles Boschetti, Xavier Roblin, et al.
United European Gastroenterology Journal|May 5, 2021
Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's diseaseAnthony Buisson, Stéphane Nancey, Luc Manlay, et al.
Inflammatory Bowel Diseases|March 25, 2015
Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's diseaseGuillaume Bouguen, David Laharie, Stéphane Nancey, et al.
The American Journal of Gastroenterology|March 18, 2015
Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn's DiseaseGilles Boschetti, Marc'harid Laidet, Driffa Moussata, et al.
Alimentary Pharmacology & Therapeutics|March 24, 2020
Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort studyMarianne Hupé, Pauline Rivière, Stephane Nancey, et al.
Tissue Barriers|June 28, 2022
Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn's disease and is responsive to filgotinibWalter Reinisch, Adrian Serone, Xavier Hébuterne, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 1, 2019
Infliximab therapy intensification upon loss of response: Is there an optimal trough level?Bella Ungar, Zohar Ben-Shatach, Gal Ben-Haim, et al.
EMBO Molecular Medicine|July 5, 2022
Alteration of microbiota antibody-mediated immune selection contributes to dysbiosis in inflammatory bowel diseasesEva Michaud, Louis Waeckel, Rémi Gayet, et al.
Retrovirology|July 2, 2016
Major influence of CD4 count at the initiation of cART on viral and immunological reservoir constitution in HIV-1 infected patientsAnne-Emmanuelle Depincé-Berger, Delphine Vergnon-Miszczycha, Alexandre Girard, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 29, 2016
Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 MonthsNicolas Williet, Gilles Boschetti, Marion Fovet, et al.
Pageof 26

Showing results (181-190 of 252) with videos related to

Sort By:
Pageof 26
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 10, 2019
Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's DiseaseNinon Soufflet, Gilles Boschetti, Xavier Roblin, et al.
United European Gastroenterology Journal|May 5, 2021
Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's diseaseAnthony Buisson, Stéphane Nancey, Luc Manlay, et al.
Inflammatory Bowel Diseases|March 25, 2015
Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's diseaseGuillaume Bouguen, David Laharie, Stéphane Nancey, et al.
The American Journal of Gastroenterology|March 18, 2015
Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn's DiseaseGilles Boschetti, Marc'harid Laidet, Driffa Moussata, et al.
Alimentary Pharmacology & Therapeutics|March 24, 2020
Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort studyMarianne Hupé, Pauline Rivière, Stephane Nancey, et al.
Tissue Barriers|June 28, 2022
Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn's disease and is responsive to filgotinibWalter Reinisch, Adrian Serone, Xavier Hébuterne, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 1, 2019
Infliximab therapy intensification upon loss of response: Is there an optimal trough level?Bella Ungar, Zohar Ben-Shatach, Gal Ben-Haim, et al.
EMBO Molecular Medicine|July 5, 2022
Alteration of microbiota antibody-mediated immune selection contributes to dysbiosis in inflammatory bowel diseasesEva Michaud, Louis Waeckel, Rémi Gayet, et al.
Retrovirology|July 2, 2016
Major influence of CD4 count at the initiation of cART on viral and immunological reservoir constitution in HIV-1 infected patientsAnne-Emmanuelle Depincé-Berger, Delphine Vergnon-Miszczycha, Alexandre Girard, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 29, 2016
Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 MonthsNicolas Williet, Gilles Boschetti, Marion Fovet, et al.
Pageof 26